|
Back to Home » November 2019 News » PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy |
PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy |
November 25, 2019
SOUTH PLAINFIELD, N.J., Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for risdiplam (RG7916) for the treatment of spinal muscular...
Source URL: https://www.prnewswire.com:443/news-releases/ptc-therapeutics-announces-fda-grants-priority-review-to-risdiplam-for-the-treatment-of-spinal-muscular-atrophy-300964301.html
|
|
|
|
